JP2012514021A5 - - Google Patents

Download PDF

Info

Publication number
JP2012514021A5
JP2012514021A5 JP2011544019A JP2011544019A JP2012514021A5 JP 2012514021 A5 JP2012514021 A5 JP 2012514021A5 JP 2011544019 A JP2011544019 A JP 2011544019A JP 2011544019 A JP2011544019 A JP 2011544019A JP 2012514021 A5 JP2012514021 A5 JP 2012514021A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
oligonucleotide
composition according
adjusted
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011544019A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012514021A (ja
JP5793423B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/067561 external-priority patent/WO2010076248A1/en
Publication of JP2012514021A publication Critical patent/JP2012514021A/ja
Publication of JP2012514021A5 publication Critical patent/JP2012514021A5/ja
Application granted granted Critical
Publication of JP5793423B2 publication Critical patent/JP5793423B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011544019A 2008-12-31 2009-12-18 急性冠症候群の治療のためのＬＮＡＡｐｏＢアンチセンスオリゴマーの使用 Expired - Fee Related JP5793423B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14184808P 2008-12-31 2008-12-31
US61/141,848 2008-12-31
PCT/EP2009/067561 WO2010076248A1 (en) 2008-12-31 2009-12-18 Use of lna apob antisense oligomers for the treatment of acute coronary syndromes

Publications (3)

Publication Number Publication Date
JP2012514021A JP2012514021A (ja) 2012-06-21
JP2012514021A5 true JP2012514021A5 (https=) 2013-02-14
JP5793423B2 JP5793423B2 (ja) 2015-10-14

Family

ID=41698255

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011544019A Expired - Fee Related JP5793423B2 (ja) 2008-12-31 2009-12-18 急性冠症候群の治療のためのＬＮＡＡｐｏＢアンチセンスオリゴマーの使用

Country Status (5)

Country Link
US (1) US9132147B2 (https=)
EP (1) EP2384197B1 (https=)
JP (1) JP5793423B2 (https=)
ES (1) ES2572361T3 (https=)
WO (1) WO2010076248A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010076248A1 (en) 2008-12-31 2010-07-08 Santaris Pharma A/S Use of lna apob antisense oligomers for the treatment of acute coronary syndromes
CA2817256A1 (en) 2010-11-12 2012-05-18 The General Hospital Corporation Polycomb-associated non-coding rnas
US9920317B2 (en) 2010-11-12 2018-03-20 The General Hospital Corporation Polycomb-associated non-coding RNAs
EA201492116A1 (ru) 2012-05-16 2015-05-29 Рана Терапьютикс, Инк. Композиции и способы для модулирования экспрессии mecp2
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
WO2013173652A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics, Inc. Compositions and methods for modulating gene expression
EP2906255B1 (en) * 2012-10-12 2023-02-22 Ionis Pharmaceuticals, Inc. Antisense compounds and uses thereof
CN104837996A (zh) * 2012-11-15 2015-08-12 罗氏创新中心哥本哈根有限公司 抗apob反义缀合物化合物
AU2014211406B2 (en) * 2013-01-30 2019-07-18 Roche Innovation Center Copenhagen A/S LNA oligonucleotide carbohydrate conjugates
SG10201803157XA (en) 2013-05-01 2018-05-30 Regulus Therapeutics Inc Microrna compounds and methods for modulating mir-122
US9506030B2 (en) 2013-05-01 2016-11-29 Regulus Therapeutics Inc. Compounds and methods for enhanced cellular uptake
JP6519842B2 (ja) * 2013-10-04 2019-05-29 国立大学法人神戸大学 福山型筋ジストロフィー治療用アンチセンス核酸
MX2016005855A (es) * 2013-11-14 2016-07-13 Roche Innovation Ct Copenhagen As Compuestos de conjugados antisentido de apolipoproteina b (apob).
WO2016033424A1 (en) * 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
WO2016070060A1 (en) 2014-10-30 2016-05-06 The General Hospital Corporation Methods for modulating atrx-dependent gene repression
WO2016149455A2 (en) 2015-03-17 2016-09-22 The General Hospital Corporation The rna interactome of polycomb repressive complex 1 (prc1)
US12005120B2 (en) 2018-05-08 2024-06-11 Regulus Therapeutics Inc. Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407943B2 (en) * 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
EP2377873B1 (en) * 2004-09-24 2014-08-20 Alnylam Pharmaceuticals, Inc. RNAi modulation of ApoB and uses thereof
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
KR20080068019A (ko) 2005-09-15 2008-07-22 산타리스 팔마 에이/에스 아포지단백질-ｂ100 발현 억제용 ｒｎａ 길항제 화합물
WO2007090071A2 (en) 2006-01-27 2007-08-09 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
WO2007107162A2 (en) * 2006-03-23 2007-09-27 Santaris Pharma A/S Small internally segmented interfering rna
EP2007888A2 (en) 2006-04-03 2008-12-31 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
AU2007249349B2 (en) 2006-05-11 2012-03-08 Isis Pharmaceuticals, Inc. 5'-Modified bicyclic nucleic acid analogs
US8470791B2 (en) 2007-03-22 2013-06-25 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
DK2173760T4 (en) 2007-06-08 2016-02-08 Isis Pharmaceuticals Inc Carbocyclic bicyclic nukleinsyreanaloge
EP2623599B1 (en) * 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Micromirs
WO2009114475A2 (en) * 2008-03-09 2009-09-17 Intradigm Corporation Compositions comprising human pcsk9 and apolipoprotein b sirna and methods of use
CA2721333C (en) * 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
WO2010076248A1 (en) 2008-12-31 2010-07-08 Santaris Pharma A/S Use of lna apob antisense oligomers for the treatment of acute coronary syndromes

Similar Documents

Publication Publication Date Title
JP2012514021A5 (https=)
HRP20210819T1 (hr) Fenfluramin za uporabu u liječenju dravet sindroma
WO2014022739A3 (en) Modified rnai agents
WO2013074974A3 (en) Modified rnai agents
WO2011063164A3 (en) Sustained release cannabinoid medicaments
BRPI1011229A2 (pt) co-suspensão, inalador de dose medida, e, métodos de preparação de um inalador de dose medida, de dispensação respiratória de um agente ativo a um paciente, e para tratar de um paciente.
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
MX2016007409A (es) Composiciones de acido ribonucleico de interferencia (ari) contra el componente del complemento y metodos para su uso.
JP2013522184A5 (https=)
MX2023008408A (es) Composiciones antisentido, y metodos para obtener y usar las mismas.
NZ597071A (en) Compositions and methods for modulation of smn2 splicing in a subject
MX366314B (es) Uso de derivados de insulina por inyecciones con intervalos variables.
PH12013501513A1 (en) Nanoparticles loaded with chemotherapeutic antitumoral drug
JP2012193216A5 (https=)
BR112013033309A2 (pt) método para tratar ou prevenir pelo menos uma afecção inflamatória em um paciente, método para inibir lesões hepáticas em um paciente em risco de lesões hepáticas químicas provenientes de drogas prescritas ou drogas de abuso, método para inibir danos de tecido mediados por célula nkt tipo i em um paciente, método para inibir a ativação de células nkt tipo i, método para inibir a ativação de células nkt tipo i em um paciente com uma doença inflamatória e método para inibir a liberação de células mieloides no fígado de um paciente
MX2011011656A (es) Uso de los inhibidores de la fosfodiesterasa 7 para el tratamiento de trastornos del movimiento.
BRPI0912842A8 (pt) composição farmacêutica, métodos para prevenir ou tratar o rubor induzido por niacina em um indivíduo, para reduzir pelo menos um sintoma de rubor relacionado com a terapia com niacina em um indivíduo, para diminuir os efeitos colaterais relacionados com a protaglandina em um indivíduo, para diminuir uma taxa de descontinuação do tratamento com niacina por um indivíduo, para aumentar a submissão do paciente ao tratamento com niacina, para tratar aterosclerose em um paciente, para tratar uma doença relacionada com um perfil de hdl baixo em um paciente, formulação do ácido nicotínico de dispensação modificada, uso da composição farmacêutica, e, microcápsula de aspirina
ECSP17000643A (es) Combinación farmacéutica que comprende 3-(3-dimetilamino-1etil-2-metil-propil)-fenol y Paracetamol.
CL2013003497A1 (es) Producto farmacéutico de combinación en forma de polvo seco para administración por medio de un inhalador que comprende una sal de umeclidinio de un grupo definido y 100 mcg/dosis de furoato de fluticasona, sin otros activos adicionales; uso para el tratamiento de enfermedades inflamatorias o del aparato respiratorio.
JP2016515586A5 (https=)
WO2014160216A3 (en) Dual targeting anticancer agents
CN110062628A (zh) 一种瑞卡帕布口服缓控释药物组合物及其用途
UY31790A (es) Utilización de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administración de dronedarona
AR094287A1 (es) Metodos y composiciones para administracion de oxibutinina
JP2015527316A5 (https=)